Form D · Biotechnology

Aprea Therapeutics, Inc.

Doylestown, PA · CIK 0001781983

Offering snapshot reported Dec 29, 2025 · SEC filing

Reported sold
$3.06M
Offering amount: $5.78M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 10, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 29, 2025Initial$3,055,822No comparison8SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$210K
Finders' fees
$0
Form D file number
021-568049
Includes up to $2,727,943.92 in offering proceeds upon the cash exercise of common stock purchase warrants.
In addition to the cash fee, Maxim Group LLC was issued a common stock purchase warrant for the purchase of up to 257,510 shares of common stock as additional compensation.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Maxim Group LLC120708

Source: Form D, filed Dec 29, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jean Pierre Bizzari Director
Marc Duey Director
Oren Gilad Director, Executive
Michael Grissinger Director
Gabriela Gruia Director
John P. Hamill Executive
John B. Henneman Director
Rifat Pamukcu Director
Richard Peters Director
Bernd Seizinger Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3805 Old Easton Road
Doylestown, PA, 18902